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SUMMARY
Cerebral cavernous malformations (CCMs) are a cause of stroke and seizure for which no medical 
therapies exist. CCMs arise from loss of an adaptor complex that negatively regulates MEKK3-
KLF2/4 signaling in brain endothelial cells, but upstream activators of this disease pathway remain 
unknown. Here, we identify endothelial TLR4 and the gut microbiome as critical stimulants of 
CCM formation. Activation of TLR4 by gram negative bacteria or lipopolysaccharide accelerates 
CCM formation, while genetic or pharmacologic blockade of TLR4 signaling prevents CCM 
formation in mice. Polymorphisms that increase expression of TLR4 or its co-receptor CD14 are 
associated with higher CCM lesion burden in humans. Germ-free mice are protected from CCM 
formation, and a single course of antibiotics permanently alters CCM susceptibility in mice. These 
studies identify unexpected roles for the microbiome and innate immune signaling in the 
pathogenesis of a cerebrovascular disease, as well as novel strategies for its treatment.
INTRODUCTION
Cerebral cavernous malformations (CCMs) are relatively common vascular malformations 
that arise predominantly in the central nervous system, causing hemorrhagic stroke and 
seizure1. CCMs arise from loss of function mutations in three genes, KRIT1, CCM2, and 
PDCD10, that encode components of a heterotrimeric, intracellular adaptor protein complex 
(the “CCM complex”)2,3. The clinical course of familial CCM disease is highly variable, 
even among individuals who share identical germline mutations4–6, suggesting the existence 
of powerful genetic and/or environmental disease modifiers. Present treatment for CCMs 
consists solely of palliative therapies or neurosurgical resection.
Recent studies of vertebrate genetic models and human CCM lesions have demonstrated that 
loss of the CCM complex results in vascular lesion formation due to increased MEKK3-
KLF2/4 signaling in brain endothelial cells7–10, and that the CCM complex suppresses 
MEKK3-KLF2/4 signaling through a direct interaction between CCM2 and MEKK311,12. 
Since effective drugs targeting the MEKK3-KLF2/4 pathway do not exist, these molecular 
insights have not had an immediate translational impact. However, they raise a key 
mechanistic question: if the role of the CCM complex is to negatively regulate MEKK3-
KLF2/4 signaling, what activates this pathway in brain endothelial cells? Identification of 
upstream activators of this pathway is needed to understand the pathogenesis of CCM 
disease and reveal viable therapeutic strategies.
RESULTS
CCM formation is driven by gram negative bacteria and lipopolysaccharide
To investigate CCM formation in mice, we generated animals in which endothelial specific 
deletion of Krit1 or Ccm2 was induced one day after birth (P1, iECre;Krit1fl/fl & 
iECre;Ccm2fl/fl). In this model, vascular malformations first appear in the cerebellar white 
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matter at P6, with numerous mature lesions present by P109,13. These mice were maintained 
as inbred breeding colonies and initially demonstrated a highly penetrant lesion phenotype 
(termed “susceptible”, Fig. 1a top). However, following a change in vivarium at the 
University of Pennsylvania, we noted the spontaneous emergence of iECre;Krit1fl/fl & 
iECre;Ccm2fl/fl sub-colonies that developed barely visible hindbrain lesions at P17 (termed 
“resistant”, Fig. 1a bottom). Previous studies have demonstrated high CCM penetrance on a 
C57BL/6J background13, but iECre;Ccm2fl/fl animals back-crossed seven generations to 
C57BL/6J remained resistant to CCM formation (Extended Data Fig. 1a). Significantly, 
among a large population of CCM-resistant animals, we detected a small number of 
individual pups that exhibited robust CCM formation in association with the presence of 
intra-abdominal, gram negative bacterial (GNB) abscesses that likely developed following 
tamoxifen injection (Fig. 1b, c and Extended Data Fig. 1b). This observation suggested that 
gram negative infection accelerates CCM pathogenesis.
To directly test the role of gram negative infection, gram negative abscesses were induced in 
resistant iECre;Ccm2fl/fl mice at P5 by intra-peritoneal injection of live Bacteroides fragilis 
(B. frag). Following B. frag injection, 9/16 resistant iECre;Ccm2fl/fl animals developed large 
CCM lesions (termed “Responders”, Fig. 1d, left), but 7/16 animals did not (termed “Non-
responders”, Fig. 1d, right). Responders to B. frag injection exhibited splenic abscesses and 
higher spleen weights compared with non-responders (Fig. 1e, f), suggesting that 
hematogenous spread of GNB from the site of abscess was required to stimulate CCM 
formation in resistant iECre;Ccm2fl/fl animals. Since GNB stimulate mammalian cellular 
responses in large part through cell membrane-derived lipopolysaccharide (LPS), we tested 
the sufficiency of LPS to drive CCM formation. Injection of LPS resulted in the formation of 
massive lesions in resistant iECre;Ccm2fl/fl animals (Fig. 1g–i), but had no effect on 
Ccm2fl/fl littermates (Extended Data Fig. 1c, d). These findings reveal that blood-borne 
GNB and LPS are strong drivers of CCM formation in mice.
Endothelial TLR4 function and brain endothelial CCM complex deficiency underlie lesion 
formation
We recently demonstrated that loss of the CCM proteins KRIT1 or CCM2 results in vascular 
malformation due to increased MEKK3 signaling in endothelial cells9. LPS activates 
intracellular signals through the innate immune receptor TLR414, and MEKK3-deficient 
fibroblasts are unable to activate downstream signaling responses to LPS in vitro15. We 
therefore hypothesized that GNB and LPS accelerate CCM formation by activating TLR4-
MEKK3-KLF2/4 signaling in CCM complex-deficient brain endothelial cells. Analysis of 
susceptible iECre;Krit1fl/fl mice revealed that CCM lesions arise in the absence of an 
immune cell infiltrate at P6 (Extended Data Fig. 2), and that a single dose of LPS at P5 
accelerated CCM formation by P6 (Fig. 2a). Consistent with a brain endothelial cell intrinsic 
mechanism, we observed synergistic effects of CCM complex-deficiency and LPS injection 
on the expression of CCM-causing genes Klf2 and Klf4, known endothelial TLR4 signaling 
targets IL-1β (Il1b) and E-selectin (Sele), as well as on the level of phospho-myosin light 
chain (Fig. 2b and Extended Data Fig. 1e).
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To directly test the requirement for endothelial TLR4 in spontaneous CCM formation, we 
bred iECre;Krit1fl/fl;Tlr4fl/+ and iECre;Krit1fl/fl;Tlr4fl/fl mice using animals from the 
susceptible iECre;Krit1fl/fl colony. Loss of a single endothelial Tlr4 allele resulted in an 
approximately 75% reduction in CCM lesion burden at P10, while loss of both resulted in 
virtually complete prevention of CCM lesion formation (Fig. 2c, d and Extended Data Fig. 
3a). Cd14 encodes a soluble TLR4 co-receptor that binds LPS and facilitates TLR4 
signaling16,17. Although less complete, global loss of CD14 also prevented CCM formation 
in susceptible iECre;Krit1fl/fl mice (Fig. 2e, f and Extended Data Fig. 3b). Lineage tracing 
studies confirmed that iECre (Cdh5(PAC)-CreERT2) transgene activity was restricted to 
endothelial cells (Extended Data Fig. 4), excluding a requirement for hematopoietic cell 
TLR4 signaling during CCM formation. Finally, to exclude a role for the CCM complex in 
endothelial cells outside the brain, we used a recently generated Slco1c1(BAC)-CreERT2 
transgene18 to further restrict deletion of Krit1 to brain endothelial cells. Slco1c1(BAC)-
CreERT2;R26-LSL-RFP animals exhibited RFP+ endothelial cells in the brain but not in the 
gut or liver (Extended Data Fig. 5a), and Slco1c1(BAC)-CreERT2;Krit1fl/fl (“iBrECre 
Krit1fl/fl”) animals developed CCM lesions like those in iECre;Krit1fl/fl animals (Extended 
Data Fig. 5b, c). These genetic findings identify endothelial TLR4 signaling as a critical 
driver of CCM formation in mice.
Polymorphisms that increase TLR4 and CD14 expression are associated with increased 
CCM lesion formation in humans
Human and mouse studies have demonstrated that TLR4 signaling positively correlates with 
receptor expression levels19,20, suggesting that polymorphisms associated with changes in 
TLR4 expression might influence the natural history of human CCM disease. We recently 
analyzed 830 genetic variants of 56 inflammatory and immune related genes in 188 human 
patients with an identical nonsense mutation in the KRIT1 gene (Q455X) in whom CCM 
lesion burden was measured using magnetic resonance imaging (MRI)6. Following statistical 
analysis, single nucleotide polymorphisms (SNPs) in only two genes, TLR4 (rs10759930, 
chromosome 9, Fig. 3a) and CD14 (rs778587, chromosome 5, Fig. 3a), were found to be 
significantly associated with increased CCM lesion number. Further analysis of genes in 
TLR4-MEKK3-KLF2/4 signaling pathways identified additional SNPs for TLR4 
(rs10759931) and CD14 (rs778588) in linkage disequilibrium with those previously 
identified (Fig. 3a), but none in other pathway genes (Materials and Methods) that associated 
with altered lesion burden. Significantly, the TLR4 and CD14 SNPs associated with 
increased CCM lesion number are in the 5′ genomic region of each gene (Fig. 3a), and 
constitute cis expression quantitative trait loci (cis-eQTLs) that positively regulate whole-
blood cell expression of TLR4 and CD14 in a dose-dependent manner corresponding with 
risk allele number (Fig. 3b–c and21,22). These results were independently corroborated by a 
similar GTEx Consortium study (Materials and Methods). MRI analysis revealed additive 
CCM lesion numbers in KRIT1 Q455X patients who carried one, two or three TLR4 or 
CD14 risk alleles (Fig. 3d–f). Carriers of TLR4 or CD14 risk alleles were associated with 
72% or 49% more lesions compared to wildtype individuals, respectively (Fig. 3e and f). 
These findings demonstrate that genetic changes associated with altered TLR4 and CD14 
expression result in coordinate changes in CCM lesion formation in both humans and mice 
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(Fig. 2c–f), supporting the hypothesis that TLR4/CD14 signaling plays a central and 
conserved role in CCM pathogenesis.
The bacterial microbiome is a primary driver of CCM formation in mice
Although endogenous TLR4 ligands have been identified23, the primary known TLR4 ligand 
is GNB-derived LPS14,24. The findings that CCM pathogenesis requires endothelial TLR4 
and CD14 (Fig. 2c–f) and that CCM susceptibility shifted dramatically with a change in 
vivarium (Fig. 1a) suggested that GNB in the microbiome may be a primary source of TLR4 
ligand and an important regulator of CCM disease. To directly test the role of the bacterial 
microbiome during CCM formation, we delivered susceptible E19.5 iECre;Krit1fl/fl neonates 
using sterile C-section and fostered them to imported conventional or germ-free Swiss 
Webster mothers (Fig. 4a). All fostered iECre;Krit1fl/fl neonates exhibited robust CCM 
formation at P10 when raised by conventional Swiss Webster mothers (Fig. 4b, c and 
Extended Data Fig. 3c). In contrast, 7/8 fostered iECre;Krit1fl/fl neonates raised in germ-free 
conditions failed to develop CCM lesions, indicating that bacteria are required for CCM 
pathogenesis in most animals (Fig. 4b–c and Extended Data Fig. 3c). A single fostered 
iECre;Krit1fl/fl neonate developed CCM lesions despite reductions in gut bacteria and Krit1 
mRNA similar to fostered iECre;Krit1fl/fl littermates that failed to develop CCMs (red 
boxes, Fig. 4b–e and Extended Data Fig. 3c). Prior studies have demonstrated that MEKK3 
is required for signaling downstream of cytokines IL-1β15 and TNFα25, and other pattern-
recognition receptors can signal in endothelial cells through the same effectors utilized by 
TLR426,27. Thus, the generation of lesions in a germ-free iECre;Krit1fl/fl neonate suggested 
that cytokines or immune receptors other than TLR4 may also drive CCM formation in vivo. 
To directly test the ability of non-TLR4 ligands to stimulate CCM formation, we 
administered IL-1β, TNFα, TLR3 ligand poly(I:C), and TLR2 ligand peptidoglycan (PGN) 
to resistant iECre;Ccm2fl/fl neonates and assessed effects on CCM formation. IL-1β and 
poly(I:C) treatment significantly increased CCM lesion volume although no difference was 
observed with TNFα or PGN (Extended Data Fig. 6). These findings identify the bacterial 
biome as a critical driver of CCM formation in vivo, but also demonstrate that cytokines and 
innate immune ligands other than LPS can support CCM formation in vivo.
CCM susceptibility is associated with specific gram negative bacteria in the gut 
microbiome
Assessment of CCM formation in iECre;Krit1fl/fl and iECre;Ccm2fl/fl mice at P10 revealed a 
remarkably binary phenotype in which susceptible mice developed numerous lesions while 
resistant mice developed virtually none (Fig. 5a–b and d–e). Lesion volumes were 
indistinguishable among susceptible iECre;Krit1fl/fl and iECre;Ccm2fl/fl animals and no 
difference in brain endothelial Tlr4 expression was detected between susceptible and 
resistant animals (Extended Data Fig. 1f), supporting a dominant role of non-genetic factors 
such as the gut microbiome in determining CCM susceptibility.
To identify specific bacteria that associate with CCM susceptibility or resistance, we 
performed 16S rRNA gene sequencing of bacterial DNA extracted from the feces of female 
mice that raised susceptible or resistant iECre;Krit1fl/fl and iECre;Ccm2fl/fl animals (Ext. 
Data Fig. 7a). A PERMANOVA test of unweighted UniFrac distances revealed clear 
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separation of susceptible and resistant bacterial microbiome communities, regardless of 
whether they were derived from iECre;Krit1fl/fl or iECre;Ccm2fl/fl colonies (p<0.0001, 
R2=0.051 Fig. 5f). Further accounting for relative abundances of bacterial species, 
significant separation between susceptible and resistant animals was also observed using 
weighted UniFrac analysis (p=0.0016, R2=0.091, Fig. 5g). Fitting generalized, linear mixed 
effects models for commonly present bacterial taxa identified one major group that differed 
significantly between the gut biomes of susceptible and resistant animals: gram negative 
Bacteroidetes s24-7 (s24-7) was significantly more abundant in susceptible animals 
irrespective of genotype (Fig. 5h, Extended Data Fig. 7b–c). Significantly, 16S sequencing 
of gut bacteria from conventional Swiss-Webster foster mothers revealed high levels of 
s24-7, explaining susceptibility to CCM formation by C-section/fostered iECre;Krit1fl/fl 
neonates (Fig. 4 and Fig. 5c–e and h). These findings support a key role for the gut 
microbiome in CCM disease pathogenesis, and suggest that CCM susceptibility can be 
significantly affected by levels of specific GNB in the gut microbiome.
CCM formation can be blocked by TLR4 antagonists or altering the microbiome
Our studies do not exclude a role for TLR4 signaling in non-brain endothelial cells. 
However, they are most consistent with a disease model in which brain endothelial TLR4/
CD14 receptors stimulate MEKK3-KLF2/4 signaling in response to GNB or GNB-derived 
LPS that translocate from the gut lumen to circulating blood (Fig. 6a)—a process 
significantly influenced by the composition of the gut microbiome28–31. This model predicts 
two novel approaches to treat CCM disease: TLR4 blockade and deliberate microbiome 
manipulation.
Tak242 (resatorvid) is a small molecule TLR4 antagonist that binds the intracellular domain 
of TLR4 and blocks signal transduction32. Treatment of susceptible iECre;Krit1fl/fl mice 
with Tak242 demonstrated an approximately 80% reduction in CCM lesion volume (Fig. 
6b–d). LPS-RS is a hypo-acetylated LPS derived from Rhodobacter sphaeroides that 
competitively antagonizes TLR433. Treatment of susceptible iECre;Krit1fl/fl mice with LPS-
RS conferred a >90% reduction in CCM lesion volume (Extended Data Fig. 8). These 
studies confirm the essential role of TLR4 signaling in CCM pathogenesis and suggest that 
TLR4 antagonists may be effective therapies.
To test the effect of deliberate microbiome manipulation on CCM formation, we designed an 
intergenerational study utilizing a single course of antibiotics to reset the microbiome (Fig. 
6e). Male-female pairs of susceptible iECre;Krit1fl/fl mice were crossed and baseline CCM 
formation was measured in the offspring at P10 (Fig. 6f ‘Generation 1 – ABX Naïve’). Next, 
the same male-female pairs were mated a second time and broad-spectrum antibiotics 
administered maternally from E14.5 to P10 prior to lesion assessment (Fig. 6g ‘Generation 2 
– Maternal ABX’). Finally, 4–6 weeks after withdrawal of antibiotics, the same male-female 
pair delivered a third litter and lesions were assessed at P10 (Fig. 6h ‘Generation 3 – Post 
ABX’). As expected, Generation 1 susceptible iECre;Krit1fl/fl mice developed numerous 
lesions (Fig. 6f, j and Extended Data Fig. 3d ). Consistent with our findings using germ-free 
animals, Generation 2 maternal antibiotic treatment reduced CCM formation by >95% (Fig. 
6g, j), in association with a 96% reduction in total gut bacterial load (Fig. 6i). Remarkably, 
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Generation 3 iECre;Krit1fl/fl offspring from the same mating pair failed to develop CCMs 
(Fig. 6h, j), despite bacterial load returning to pre-antibiotic levels (Fig. 6i), except for a 
single Generation 3 animal that developed an intra-abdominal abscess with pronounced 
splenomegaly (Fig. 6j, star, Extended Data Fig. 9a). Maternal treatment with vancomycin 
alone, a broad-spectrum antibiotic specific for gram positive bacteria, had no effect on CCM 
formation, consistent with a causal role for GNB (Extended Data Fig. 9b–h). Measurement 
of s24-7 levels in the intestines of Generation 1, 2 and 3 neonates harvested for analysis of 
lesion volume revealed a significant, sustained reduction in Generation 3 relative to 
Generation 1 (Fig. 6k–l), consistent with the observation that resistant Krit1fl/fl and Ccm2fl/fl 
mothers have lower s24-7 levels than susceptible mothers (Fig. 5h). Conversely, sterile C-
section/fostering of resistant iECre;Krit1fl/fl and iECre;Ccm2fl/fl pups to conventional Swiss-
Webster foster mothers with high levels of s24-7 (Fig. 5h) restored CCM susceptibility 
(Extended Data Fig. 10). These findings provide further evidence that qualitative changes in 
the bacterial microbiome can alter disease course.
DISCUSSION
Designing rational therapies for CCM disease is complicated by the fact that many of the 
pathogenic events take place within brain endothelial cells of the central nervous system 
(CNS), where drug delivery is blocked by the blood-brain barrier (BBB)34. The finding that 
LPS accelerates CCM formation (Fig. 2a–e) although it is unable to cross the BBB35 
suggests that CCM formation is driven by activation of endothelial TLR4 receptors on the 
luminal, blood side of the BBB (Fig. 6a). Tak242 or LPS-RS effectively reduce lesion 
formation, confirming endothelial TLR4 as a “druggable” target for CCM disease (Fig. 6b–d 
and Extended Data Fig. 8). Existing TLR4 blocking agents developed for sepsis treatment36 
could potentially be repurposed as therapies for severe human CCM disease. However, such 
application will first need to address the requirement for chronic therapy, the potential risk 
of lethal sepsis, and whether anti-TLR4 therapy will affect existing as well as nascent 
lesions.
Manipulation of gut microbiome-host interactions is a more exciting potential strategy to 
treat a life-long disease such as CCM. The microbiome has been associated with many 
human diseases37, but specific molecular mechanisms by which it contributes to disease 
pathogenesis have been difficult to define. Our studies support a central role for the gut 
microbiome and endothelial responses to GNB in the pathogenesis of CCMs. We find that 
the bacterial microbiome is the primary source of TLR4 ligand required to stimulate CCM 
formation in mice, and that small qualitative differences in the gut microbiome may have 
dramatic effects on the course of CCM disease in this animal model. Although s24-7 is not 
found in humans, the association of CCM disease susceptibility with this GNB is 
particularly interesting because it is associated with disruption of the gut epithelial barrier38. 
Thus, a key step in CCM pathogenesis is predicted to be translocation of bacteria or bacterial 
LPS from the gut lumen into circulation (Fig. 6a). Whether similar inflammatory/colitogenic 
microbiomes also accelerate human CCM disease remains an important question. The 
clinical course of CCM disease is exceptionally variable, even among individuals with 
familial CCM disease due to a common KRIT1 mutation4,6. Genetic polymorphisms that 
alter TLR4 and CD14 expression account for some of this heterogeneity (Fig. 3), but most of 
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the clinical variability remains unexplained and may reflect the effect of individual 
microbiomes. Future studies that simultaneously define the genomes and microbiomes of 
CCM patients will be required to test this intriguing hypothesis and determine whether the 
microbiome is a viable therapeutic target for this disease.
Methods
University of Pennsylvania (Philadelphia) Mice
The Cdh5(PAC)-CreERT2 transgenic mice (iECre) were a generous gift from Ralf H. 
Adams39. Krit1fl/fl and Ccm2fl/fl animals have been previously described40,41. Tlr4fl/fl, 
Cd14−/−, Ai14 (R26-LSL-RFP), and R26-CreERT2 animals42–45 were obtained from the 
Jackson Laboratories. The Slco1c1(BAC)-CreERT2 transgenic mice (iBrECre) have been 
previously described18. All experimental animals were maintained on a mixed 129/SvJ, 
C57BL/6J, DBA/2J genetic background unless specifically described. C57BL/6J and timed 
pregnant Swiss Webster mice were purchased from Charles River Laboratories. Germ-free 
Swiss Webster mice were purchased from Taconic. Breeding pairs between two and ten 
months of age were used to generate the neonatal CCM mouse model pups. Mice were 
housed in a specific pathogen-free facility where cages were changed on a weekly basis; 
ventilated cages, bedding, food, and acidified water (pH 2.5–3.0) were autoclaved prior to 
use, ambient temperature maintained at 23°C, and 5% Clidox-STM was utilized as a 
disinfectant. Experimental breeding cages were randomly housed on three different racks in 
the vivarium, and all cages were kept on automatic 12-hour light/dark cycles. The University 
of Pennsylvania Institutional Animal Care and Use Committee (IACUC) approved all 
animal protocols, and all procedures were performed in accordance with these protocols.
Centenary Institute (Australia) Mice
A portion of the resistant iECre;Ccm2fl/fl colony was exported to the Centenary Institute, 
Sydney, Australia where the mice were permanently maintained as an inbred colony in a 
quarantine facility. After several generations, this colony uniformly converted to lesion 
susceptibility. Cages were changed on a weekly basis; ventilated cages, bedding, food, and 
acidified water (pH 2.5–3.0) were autoclaved prior to use. Ambient temperature was 
maintained between 22–26°C, and 80% ethanol and F10SCTM (1:125 dilution of the 
concentrate, a quaternary ammonium compound) were used as disinfectants. Experimental 
breeding cages were randomly distributed throughout the vivarium, and all cages were kept 
on 12-hour light/dark cycles. The Sydney Local Health District Animal Welfare Committee 
approved all animal ethics and protocols. All experiments were conducted under the 
guidelines/regulations of Centenary Institute and the University of Sydney.
Gnotobiotic animal husbandry
Germ free Swiss Webster mice were purchased from Taconic and directly transferred into 
sterile isolators (Class Biologically Clean Ltd.) under the care of the Penn Gnotobiotic 
Mouse Facility. Food, bedding, and water (non-acidified) were autoclaved prior to transfer 
into the sterile isolators. Ventilated cages were changed weekly, and all cages in the 
vivarium were kept under 12-hour light/dark cycles. Microbiology testing (aerobic and 
anaerobic culture, 16S qPCR) was performed every ten days and fecal samples were sent to 
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Charles Rivers Laboratories for pathology testing on a quarterly basis. Further details 
regarding the sterile C-section fostering can be found below. The University of Pennsylvania 
Institutional Animal Care and Use Committee (IACUC) approved all animal protocols, and 
all procedures were performed in accordance with these protocols.
Induction of the neonatal CCM mouse model
For all neonatal CCM mouse model experiments, at one-day post-birth (P1), pups were 
intragastrically injected by 30-gauge needle with 40 μg of 4-hydroxytamoxifen (4OHT, 
Sigma Aldrich, H7904) dissolved in a 9% ethanol/corn oil (volume/volume) vehicle (50 μL 
total volume per injection). This solution was freshly prepared from pre-measured, 4OHT 
powder for every injection. Prior to injection, the pup skin was sanitized using ethanol 
wipes. The P1 time point was defined by checking experimental breeding pairs every 
evening for new litters. The following morning (P1), pups were injected with 4OHT. All 
experimental pups were subjected to this induction regimen. For the Tlr4 rescue experiment 
(Fig. 2), and all lineage tracing experiments, an additional dose of 40 μg 4OHT was 
intragastrically delivered at P2 (P1+2, two total doses). Pups were then harvested as 
previously described9 at the specified time points.
Histology
Tissue samples were fixed in 4% formaldehyde overnight, dehydrated in 100% ethanol, and 
embedded in paraffin. 5 μm thick sections were used for hematoxylin & eosin and 
immunohistochemistry staining. The following antibodies were used for immunostaining: rat 
anti-PECAM (1:20, Histo Bio Tech DIA-310), rabbit anti-pMLC2 (1:200, Cell Signaling 
3674S), goat anti-KLF4 (1:100, R&D AF3158), and rabbit anti-RFP (1:50, Rockland 
600-401-379). Littermate control and experimental animal sections were placed on the same 
slide and immunostained at the same time under identical conditions. Images were taken at 
the same time using the same exposure times and color channels, and were subsequently 
overlaid using ImageJ.
Gram staining
Intra-abdominal abscesses were dissected and triturated in 500 μL of SOC medium. Drops 
of the mixture were placed on a microscope slide, briefly exposed to heat, and gram staining 
was performed using a kit from Sigma Aldrich (77730) following the manufacturer’s 
protocol.
Whole-mount retinal endothelium staining
Eyes from euthanized P17 mice were removed and fixed overnight in cold 4% PFA/PBS 
solution. The following day, retinas were dissected, cut into petals, and stained with 
isolectin-B4 conjugated to Alexa488 fluorophore (Thermo Fisher I21411) as previously 
described46. The retinas were then whole-mounted on microscopy slides in a flat, four-petal 
shape for fluorescence imaging.
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Bacteroides fragilis (B. frag) abscess model
B. frag was purchased directly from the ATCC (strain 25285) and grown in chopped meat 
glucose (CMG) broth (Anaerobe Systems AS-813) under anaerobic conditions at 37°C. 
Autoclaved, degassed cecal contents (ACC) were generated by harvesting cecal contents 
from the colons of euthanized adult mice between 2–8 months of age. Cecal contents were 
then autoclaved and pulverized in an equal volume of CMG broth. This slurry was filtered 
through a 70 μm nylon strainer and degassed overnight in the anaerobic chamber. One mL of 
CMG broth was inoculated with B. frag and grown overnight to an optical density between 
0.8 and 1.0. An equal volume of ACC was mixed with the overnight bacterial culture. 100 
μL of this B. frag/ACC mixture was injected intraperitoneally into five-day old pups with a 
31-gauge needle. Control littermates were simultaneously injected intraperitoneally with 100 
μL of ACC alone. Pups were harvested at P17. Spleen weight was measured immediately 
after dissection, and all tissue was subsequently processed as described above.
Intravenous lipopolysaccharide (LPS), peptidoglycan (PGN), polyinosinic:polycytidylic 
acid (poly(I:C)), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNFα) 
injections
Lipopolysaccharide from E. coli O127:B8 was purchased from Sigma (L3129) and 
administered to the low lesion penetrance, resistant iECre;Ccm2fl/fl neonatal CCM disease 
model. At P5, a 3 μg dose of LPS dissolved in sterile PBS was administered retro-orbitally 
(RO) in a total 30 μL volume by 31-gauge needle. At P10, a 5 μg dose of LPS was 
administered RO in a total 50 μL volume by 31-gauge needle. Control animals were 
identically injected with PBS alone. Pups were euthanized and brains dissected at specified 
time points. PGN from Bacillus subtilis (a gram-positive gut commensal) was purchased 
from Invivogen (tlrl-pgnb3) and administered to the resistant iECre;Ccm2fl/fl neonatal CCM 
disease model under identical conditions as the LPS experiments. Poly(I:C) was purchased 
from Invivogen (tlrl-picw) and administered to the resistant iECre;Ccm2fl/fl neonatal CCM 
disease model under identical conditions as the LPS experiments.
Mouse IL-1β was purchased from Genscript (Z02988) and administered to the resistant 
iECre;Ccm2fl/fl neonatal CCM disease model. At P5, a 5 ng dose of IL-1β dissolved in 
sterile PBS was administered RO in a total 30 μL volume by 31-gauge needle. At P10, an 8 
ng dose of IL-1β was administered RO in a total 50 μL volume by 31-gauge needle. Control 
animals were identically injected with PBS alone. Pups were euthanized and brains dissected 
at specified time points. Mouse TNFα was purchased from Genscript (Z02918) and 
administered to the resistant iECre;Ccm2fl/fl neonatal CCM disease model under identical 
conditions as the IL-1β experiments.
Contrast-enhanced, X-ray micro-computed tomography (microCT)
For all experiments utilizing microCT quantification of CCM lesion volume, brains were 
harvested and immediately placed in 4% PFA/PBS fixative. Brains remained in fixative until 
staining with non-destructive, iodine contrast and subsequent microCT imaging performed 
as previously described47. Importantly, all tissue processing, imaging, and volume 
quantification were done in a blinded manner by investigators at The University of Chicago 
without any knowledge of experimental details.
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As previously done, we blinded samples at three distinct points in the analysis. First, 
neonatal CCM model pups were injected with 4OHT without knowledge of genotypes. 
Second, hindbrains from genotyped animals were given randomized, de-identified labels to 
provide for blinded microCT scanning by an independent operator. Third, randomized 
microCT image stacks were analyzed in a blinded manner by individuals not involved in any 
prior experimental steps.
Immune cell isolation from neonatal brain
Mice were anesthetized with AvertinTM and underwent intra-cardic perfusion with 10 mL of 
cold PBS. The brain was separated from the brainstem, and the cerebellum was separated 
from the remaining brain and processed in parallel. The tissue was minced with scissors, 
placed in digestion buffer (RPMI, 20mM HEPES, 10% FCS, 1mM CaCl2, 1mM MgCl2, 
0.05mg/ml Liberase TM (Sigma), 0.02mg/ml DNase I (Sigma)), and incubated for 40 min at 
37 °C with shaking at 200 rpm. The mixture was passed through a 100 μm strainer and 
washed with FACS Buffer (PBS, 1% FBS). Cells were resuspended in 4 mL of 40% Percoll 
(GE Healthcare) and overlaid on 4 mL of 67% Percoll. Gradients were centrifuged at 400 xg 
for 20 min at 4 °C and cells at the interface were collected, washed with 10 mL of FACS 
Buffer, and stained for flow cytometric analysis.
Hematopoietic cell isolation from neonatal whole blood, spleen and subsequent FACs 
analysis
Neonatal P10 mice were anesthetized with AvertinTM and underwent intracardiac puncture/
blood draw using a 27 gauge needle/syringe coated with 0.5 M EDTA, pH 8.0 immediately 
prior to use. Cells were pelleted by centrifugation at 300 xg for 5 minutes at 4°C. Serum was 
removed and RBCs were lysed using ACK lysis buffer. Spleens were dissected in parallel, 
hand-homogenized using a mini-pestle and RBCs were lysed using ACK lysis buffer. Cells 
from both sets of tissues were passed through a 70 μm cell-strainer, pelleted, and 
resuspended in FACS buffer (PBS, 2% FBS, 0.1% NaN3) for immunostaining and 
subsequent FACS analysis.
Immune cell staining and flow cytometry analysis
Cells were isolated from the indicated tissues. Single-cell suspensions were stained with 
CD16/32 and with indicated fluorochrome-conjugated antibodies. Live/Dead Fixable Violet 
Cell Stain Kit (Invitrogen) was used to exclude non-viable cells. Multi-laser, flow cytometry 
analysis procedures were done at the University of Pennsylvania Flow Cytometry and Cell 
Sorting Facility using BD LSRII cell analyzers running FACSDiva software (BD 
Biosciences). Two-laser, flow cytometry analyses were done at the University of 
Pennsylvania iPS Cell Core using BD Accuri C6 instruments. FlowJo software (v.10 
TreeStar) was used for data analysis and graphics rendering. All fluorochrome-conjugated 
antibodies used are listed as follows (Clone, Company, Catalog Number): CD11b (M1/70, 
Biolegend, 101255); CD11c (N418, Biolegend, 117318); CD16/32 (93, Biolegend, 101319); 
CD16/32 (93, eBiosciences, 56D0161D80); CD19 (6D5, Biolegend, 115510); CD3ε 
(145D2C11, Biolegend, 100304); CD4 (GK1.5, Biolegend, 100406); CD45 (30-F11, 
Biolegend, 103121 or 103151), CD8a (53D6.7, Biolegend, 100725); Foxp3 (FJK-16s, 
eBiosciences, 50-5773-82); Ly-6G (1A8, Biolegend, 127624); Live/Dead (N/A, 
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Thermofisher, LD34966); NK1.1 (PK136, Biolegend, 108745); RORγt (B2D, eBiosciences, 
12-6981-82); Siglec-F (E50D2440, BD, 562757); TCRγδ (UC7-13D5, Biolegend, 107504)
Isolation of cerebellar endothelial cells, lung endothelial cells, and gene expression 
analysis
At the specified time points, cerebellar endothelial cells were isolated through enzymatic 
digestion followed by separation using magnetic-activated cell sorting by anti-CD31 
conjugated magnetic beads (MACS MS system, Miltenyl Biotec), as previously described9. 
Lung endothelial cells were isolated through enzymatic digestion as previously described 
followed by separation using anti-CD31 conjugated magnetic beads and the MACS MS 
system48. Isolated endothelial cells were pelleted and total RNA was extracted using the 
RNeasy Micro kit (Qiagen 74004). For qPCR analysis, cDNA was synthesized from 300 ng 
to 500 ng total RNA using the SuperScriptTM VILO cDNA Synthesis Kit and Master Mix 
(Thermo Fisher 11755050). Real-time PCR was performed with Power SYBR Green PCR 
Master Mix (Thermo Fisher 4368577) using the primers listed:
mGapdh Forward: 5′- AAATGGTGAAGGTCGGTGTGAACG -3′
mGapdh Reverse: 5′- ATCTCCACTTTGCCACTGC -3′
mKlf2 Forward: 5′- CGCCTCGGGTTCATTTC -3′
mKlf2 Reverse: 5′- AGCCTATCTTGCCGTCCTTT -3′
mKlf4 Forward: 5′- GTGCCCCGACTAACCGTTG -3′
mKlf4 Reverse: 5′- GTCGTTGAACTCCTCGGTCT -3′
mKrit1 Forward: 5′- CCGACCTTCTCCCCTTGAAC -3′
mKrit1 Reverse: 5′- TCTTCCACAACGCTGCTCAT -3′
mIl1b Forward: 5′- GCAACTGTTCCTGAACTCAACT -3′
mIl1b Reverse: 5′- ATCTTTTGGGGTCCGTCAACT -3′
mSele Forward: 5′- ATGCCTCGCGCTTTCTCTC -3′
mSele Reverse: 5′- GTAGTCCCGCTGACAGTATGC -3′
mTlr4 Forward: 5′- ACTGGGGACAATTCACTAGAGC -3′
mTlr4 Reverse: 5′- GAGGCCAATTTTGTCTCCACA -3′
Identification of human CCM associated single nucleotide polymorphisms
As part of the Brain Vascular Malformation Consortium (BVMC) CCM study (Project 1), a 
large cohort of familial CCM individuals with identical KRIT1 Q455X mutations were 
enrolled between 2009 – 2014 at the University of New Mexico. All study protocols were 
approved by the Institutional Review Boards at the University of New Mexico and 
University of California San Francisco (UCSF) and all procedures were done in accordance 
with these protocols. Prior to participation in the study, written informed consent was 
obtained from every patient and properly documented by UNM investigators.
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At study enrollment, participants received a neurological examination (LM) and 3T MRI 
imaging using a volume T1 acquisition (MPRAGE, 1-mm slice reconstruction) and axial 
TSE T2, T2 gradient recall, susceptibility-weighted, and FLAIR sequences. Lesion counting 
by the neuroradiologist (BH) was based on concurrent evaluation of axial susceptibility-
weighted imaging with 1.5-mm reconstructed images and axial T2 gradient echo 3-mm 
images.
Participants also provided blood or saliva samples for genetic studies. Genomic DNA was 
extracted using standard protocols. De-identified samples were normalized, plated on 96-
well plates, and genotyped at the UCSF Genomics Core Facility using the Affymetrix 
Axiom Genome-wide LAT1 Human Array. Affymetrix Genotyping Console (GTC) 4.1 
Software package was used to generate quality control metrics and genotype calls. All 
samples had genotyping call rates of ≥97% and were further checked for sample mix-ups 
(sex check, Mendelian errors and cryptic relatedness), resulting in 188 samples for genetic 
analysis.
21 candidate genes were further examined in the TLR4 and MEKK3-KLF2/4 signaling 
pathways (TLR4, CD14, MD-2, LBP, MYD88, TICAM1, TIRAP, TRAF1-6, MAP3K3, 
MEK5, ERK5, MEF2C, KLF2, KLF4, ADAMTS4, ADAMTS5) including 467 SNPs within 
20kb upstream or downstream of each gene locus using UCSC Genome Browser coordinates 
(GRCh37/hg19). Because total lesion counts are highly right skewed, raw counts were log-
transformed and analysis was performed on residuals (adjusted for age at enrollment and 
sex). To identify genotypes associated with log-transformed residual counts, linear 
regression analysis was implemented using QFAM family-based association tests for 
quantitative traits (PLINK v1.07 software), with stringent multiple testing correction 
(Bonferroni correction for the number of SNPs tested within each gene) given that some 
SNPs on the Affymetrix array were in linkage disequilibrium with each other, i.e., 
statistically correlated with r2>0.8.
Characterization of human cis-eQTLs
The Fehrmann dataset used for eQTL lookups consisted of peripheral blood samples from 
the United Kingdom and Netherlands49,50. Samples were genotyped with Illumina 
HumanHap300, HumanHap370 or 610 Quad platforms. Genotypes were input by Impute 
v251 using the GIANT 1000G p1v3 integrated call set for all ancestries as a reference52. 
Gene expression levels were measured by Illumina HT12v3 arrays. Gene expression pre-
processing involved quantile normalization, log2 transformation, probe centering and 
scaling, population stratification correction (first 4 genetic multidimensional scaling 
components were removed from gene expression data) and correction for unknown 
confounders (first 20 gene expression principal components not associated with genetic 
variants were removed from gene expression data). Identification of potential sample mix-
ups was conducted by MixupMapper21 and finally 1,227 samples remained. All pre-
processing steps were performed with the QTL mapping pipeline v1.2.4D (https://
molgenis26.target.rug.nl/downloads/eqtl-mapping-pipeline-1.2.4D-SNAPSHOT-dist.tar.gz).
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These results are corroborated by an independently conducted GTEX Consortium study 
(http://www.gtexportal.org/home/snp/rs10759930 and http://www.gtexportal.org/home/snp/
rs778587).
Tak242 and LPS-RS administration
Tak242 was purchased from EMD Millipore (614316) and administered to the neonatal 
CCM disease model. Five, seven, and nine days after birth, a 60 μg dose of Tak242 was 
dissolved in DMSO/sterile intralipid (Sigma, I141) vehicle and administered RO in a total 
volume of 30 μL. Control animals were identically injected with sterile DMSO/intralipid 
vehicle alone. Pups were euthanized and brains dissected 10 days after birth.
LPS-RS ultrapure was purchased from Invivogen (tlrl-prslps) and administered to the 
neonatal CCM disease model. Starting at P5, a 20 μg dose dissolved in sterile PBS was 
administered RO in a total volume of 30 μL every 24 hours. Control animals were identically 
injected with sterile PBS alone. Pups were euthanized and brains dissected 10 days after 
birth.
Transgenerational antibiotic administration
Experimental breeding pairs of mice, yielding susceptible neonatal CCM pups, were 
identified by induction of a neonatal CCM litter and evaluation of lesion burden. These 
breeding pairs then underwent timed matings and at E14.5, both male and female adult mice 
were subject to antibiotic-laced drinking water mixed with 40 g/L of sucralose and red food 
coloring. Antibiotic water was replaced daily. The following antibiotics were mixed with 
0.22 μm-filtered water: penicillin (500 mg/L), neomycin (500 mg/L), streptomycin (500 
mg/L), metronidazole (1 g/L), and vancomycin (1g/L). Antibiotics were purchased from the 
Hospital of the University of Pennsylvania pharmacy. The neonatal CCM model was 
induced as described above. At P10, pups were euthanized and antibiotic water switched for 
normal drinking water. Experimental breeding pairs were then mated to obtain third 
generation, post-antibiotic pups.
Vancomycin mono-antibiotic administration
Co-housed, susceptible Krit1fl/fl females underwent evening-morning timed matings with a 
single susceptible iECre;Krit1fl/fl male. Upon detection of a plug in the morning, the females 
were subsequently separated into singly-housed cages. At E14.5, female mice were subject 
to either vancomycin (1 g/L)-laced or untreated (vehicle) sterile-filtered drinking water, 
changed daily. The drinking water was further mixed with 40 g/L sucralose and red food 
coloring. Pups were harvested at P11.
Bacterial DNA extraction from neonatal mouse guts and bacterial rDNA qPCR
The entire neonatal gut was dissected, snap-frozen on dry ice, and stored at −80°C. The 
QIAamp DNA Stool Mini Kit (Qiagen 51504 or 51604) was used to extract bacterial DNA 
from the neonatal gut. Prior to commencing the standard Qiagen protocol, the frozen gut 
was mixed in the included stool lysis buffer and homogenized with a 5 mm stainless steel 
bead in a TissueLyser LT (Qiagen 69980) at 50 hz for 10 minutes at 4°C. Concentration of 
the extracted DNA was equalized and 16 ng of DNA was used per qPCR reaction with 
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universal bacterial 16S rRNA gene primers53, two different sets of previously characterized 
Bacteroidetes s24-7 primers54,55, and Firmicutes primers56.
Universal 16S rRNA Forward: 5′- ACTGAGAYACGGYCCA -3′
Universal 16S rRNA Reverse: 5′- TTACCGCGGCTGCTGGC -3′
Bacteroidetes s24-7 rRNA set 1 Forward: 5′- GGAGAGTACCCGGAGAAAAAGC 
-3′
Bacteroidetes s24-7 rRNA set 1 Reverse: 5′- TTCCGCATACTTCTCGCCCA -3′
Bacteroidetes s24-7 rRNA set 2 Forward: 5′- CCAGCAGCCGCGGTAATA -3′
Bacteroidetes s24-7 rRNA set 2 Reverse: 5′- CGCATTCCGCATACTTCTC -3′
Firmicutes rRNA Forward: 5′- TGAAACTYAAAGGAATTGACG -3′
Firmicutes rRNA Reverse: 5′- ACCATGCACCACCTGTC -3′
Sterile C-section and fostering to conventional Swiss Webster recipient females
Evening-morning timed matings to generate donor susceptible or resistant females yielding 
iECre;Krit1fl/fl or iECre;Ccm2fl/fl pups were performed and timed pregnant Swiss Webster 
females (Charles River 024) were ordered to serve as foster mothers. To prevent delivery of 
the pups, at E16.5, donor females were injected subcutaneously with 100 μL of a 15 μg/mL 
solution of medroxyprogesterone (Sigma Aldrich, M1629) dissolved in DMSO. The 
morning of E19.5, the donor mother was euthanized by cervical dislocation and submerged 
in a warm sterile solution of 1% VirkonSTM/PBS (weight/volume) for one minute. The 
uterus was then dissected in a sterile laminar flow hood, submerged in a warm sterile 
solution of 1% VirkonSTM/PBS for one minute and quickly rinsed with warm sterile PBS. 
Pups were then removed from the uterus and fostered to the Swiss Webster recipient female. 
The following morning, induction of the neonatal CCM model was performed as described 
above.
Sterile C-section and fostering to germ-free Swiss Webster recipient females
Timed matings were performed using germ-free Swiss Webster mice housed in sterile 
isolators under care of the University of Pennsylvania Gnotobiotic Mouse Facility. 
Simultaneous evening-morning timed matings were also performed using co-housed, 
susceptible Krit1fl/fl females and iECre;Krit1fl/fl males previously characterized to yield 
CCM-susceptible pups. Medroxyprogesterone was administered to donor females and the 
sterile C-section was performed at E19.5 as described in the previous section. The intact 
uterus was passed through a J-tube filled with warm 1% VirkonSTM/PBS that was 
hermetically sealed to the sterile isolator. Pups were dissected from the uterus inside the 
sterile isolator and fostered to the recipient germ-free Swiss Webster mother. Approximately 
one week later, fecal samples were collected for microbiology testing. Germ-free status was 
further confirmed by 16S qPCR of bacterial DNA isolated from maternal feces and neonatal 
guts.
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Collection of maternal CCM mouse feces
Fresh fecal pellets were collected from experimental females yielding susceptible or 
resistant pups one day after harvesting the pups to determine phenotypic severity. Collection 
was performed between four and six PM, pellets were immediately snap-frozen on dry ice, 
and stored at −80°C.
Extraction and library preparation of bacterial DNA for 16S rRNA gene sequencing
DNA was extracted from stool samples using the Power Soil htp kit (Mo Bio Laboratories, 
Carlsbad, CA, USA) following the manufacturer’s protocol. Library preparation was 
performed by utilizing previously described barcoded primers targeting the V1 V2 region of 
the 16S rRNA gene57. PCR reactions were performed in quadruplicate using AccuPrime Taq 
DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA). Each PCR reaction 
consisted of 0.4 μM primers, 1x AccuPrime Buffer II, 1 U Taq, and 25 ng DNA. PCRs were 
run using the following parameters: 95°C for 5 min; 20 cycles of 95°C for 30 sec, 56°C for 
30 sec, and 72°C for 90 sec; and 72°C for 8 min. Quadruplicate PCR reactions were pooled 
and products were purified using AMPureXP beads (Beckman-Coulter, Brea, CA, USA). 
Equimolar amounts from each sample were pooled to produce the final library. Positive and 
negative controls were carried through the amplification, purification, and pooling 
procedures. Negative controls were used to assess reagent contamination and consisted of 
extraction blanks and DNA-free water. Positive controls were used to assess amplification 
and sequencing quality and consisted of gBlock DNA (Integrated DNA Technologies, 
Coralville, Iowa, USA) containing non- bacterial 16S rRNA gene sequences flanked by 
bacterial V1 and V2 primer binding sites. Paired-end 2x250bp sequence reads were obtained 
from the MiSeq (Illumina, San Diego, CA, USA) using the 500 cycle v2 kit (Illumina, San 
Diego, CA, USA).
Analysis of 16S sequencing
Sequence data were processed using QIIME version 1.9.158. Read pairs were joined to form 
a complete V1V2 amplicon sequence. Resulting sequences were quality filtered and 
demultiplexed. Operational Taxonomic Units (OTUs) were selected by clustering reads at 
97% sequence similarity59. Taxonomy was assigned to each OTU with a 90% sequence 
similarity threshold using the Greengenes reference database60. A phylogenetic tree was 
inferred from the OTU data using FastTree61. The phylogenetic tree was then used to 
calculate weighted and unweighted UniFrac distances between each pair of samples in the 
study62,63. Microbiome compositional differences were visualized using Principle 
Coordinates Analysis (PCoA). Community-level differences between mice genetic 
background as well as disease susceptibility groups were assessed using a PERMANOVA 
test64 of weighted and unweighted UniFrac distances. To assess significance in the 
PERMANOVA test, each cage was randomly re-assigned to groups 9999 times. Differential 
abundance was assessed for taxa present in at least 80% of the samples, using generalized 
linear mixed effects models. For tests of taxon abundance, the cage was modeled as a 
random effect, as previous research has established that the fecal microbiota of mice are 
correlated within cages65. The p-values were corrected for multiple testing using Benjamini-
Hochberg method.
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Statistics
Sample sizes were estimated based on our previous experience with the neonatal CCM 
model and lesion volume quantitation by microCT9. Using forty historically collected, 
susceptible iECre;Krit1fl/fl and iECre;Ccm2fl/fl P10 brains, we calculated a sample standard 
deviation of 0.250 mm3. Between iECre;Krit1fl/fl and iECre;Ccm2fl/fl genotypes, an F-test to 
compare variances confirmed no significant difference (p=0.340). Thus, for a two-group 
comparison of lesion volumes, each sample group requires seven animals for a desired 
statistical power of 95% (β= 0.05), and a conventional significance threshold of 5% (α= 
0.05) assuming an effect size of 50% (0.5) and equal standard deviations between sample 
groups. These predictive calculations were corroborated by our recent publication in which 
larger effect sizes (>90%) were found to be statistically significant with four to five samples 
per group9. All experimental and control animals were littermates and none were excluded 
from analysis at the time of harvest. Experimental animals were lost or excluded at two pre-
defined points: (i) failure to properly inject 4OHT and observation of significant leakage; (ii) 
death prior to P10 because of injection or chaos. Given the early time points, no attempt was 
made to distinguish or segregate results based on neonatal genders. P-values were calculated 
as indicated in figure legends using an unpaired, two-tailed Student’s t-test; one-way 
ANOVA with multiple comparison corrections (Holm-Sidak or Bonferroni); PERMANOVA; 
or linear mixed effects modeling. As indicated in the figure legends, the standard error of the 
mean (s.e.m.), 95% confidence interval, or boxplot is shown.
Data availability
All relevant data are available from the authors upon request.
Tang et al. Page 17
Nature. Author manuscript; available in PMC 2018 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data
Extended Data Figure 1. CCM formation in resistant iECre;Ccm2fl/fl animals is stimulated by 
abscess formation and LPS
a, Resistance to CCM formation is maintained in a C57BL/6J strain background. 
iECre;Ccm2fl/fl animals were back-crossed 7 generations onto a C57BL/6J background and 
gene deletion induced at P1 with visual hindbrain assessment at P10. N=7. Scale bars, 1 mm. 
b, Retinal CCM formation is stimulated by gram negative bacterial infection. Retinas of P17 
resistant iECre;Ccm2fl/fl littermates are shown. The sample shown below is from the animal 
that developed the spontaneous gram negative abscess shown in Fig. 1c. Scale bars, 500 μm. 
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c–d, Administration of LPS does not drive CCM formation in Cre-negative neonatal mice. 
LPS was administered intravenously to Ccm2fl/fl and iECre;Ccm2fl/fl littermates as shown in 
Figure 1g, and hindbrains assessed at P17 visually (c) and histologically (H&E staining, d). 
N≥3 per group. Scale bars, 1 mm (c) and 100 μm (d). e, LPS induces myosin light chain 
activation in CCM-deficient brain endothelial cells. Phospho-myosin light chain (pMLC) 
and PECAM staining of hindbrains from P5 LPS- or vehicle-injected resistant 
iECre;Ccm2fl/fl littermates. Dotted lines trace the purkinje cell layer. N≥4 per group. Scale 
bars, 50 μm. f, Tlr4 expression does not differ between CCM susceptible and resistant 
animals. Tlr4 expression was measured using qPCR in cerebellar endothelial cells isolated 
from the indicated animals at P10. Error bars shown as s.e.m. and significance determined 
by unpaired, two-tailed Student’s t-test. n.s. indicates p>0.05.
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Extended Data Figure 2. Analysis of immune cells in P6 and P11 Krit1fl/fl and iECre;Krit1fl/fl 
brains
a, Gating strategy for B cells, NK cells, γδ T cells, CD4 T cells, CD8 T cells, eosinophils, 
neutrophils and monocytes/macrophages from cerebrum and cerebellum is shown. Cellular 
surface markers used were as follows: Neutrophils (CD45+, CD11b+, Ly6-G+), Eosinophils 
(CD45+, CD11b+, CD11c−, Ly6G−, Siglec-F+, SSChi), Monocyte/Macrophage (CD45+, 
CD11b+, CD11c−, Ly6G−, Siglec-F−, SSClo), NK cells (CD45+, CD11b−, CD19−, NK1.1+), 
B cells (CD45+, CD11b−, NK1.1−, CD19+), γδ T cell (CD45+, CD11b−, NK1.1−, CD19−, 
CD3+, TCRγδ+), CD4 T cell (CD45+, CD11b−, NK1.1−, CD19−, CD3+, TCRγδ−, CD8−, 
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CD4+), CD8 T cell (CD45+, CD11b−, NK1.1−, CD19−, CD3+, TCRγδ−, CD4−, CD8+). b, 
The number of B cells, NK cells, γδ T cells, CD4 T cells, CD8 T cells, eosinophils, 
neutrophils, and monocytes/macrophages isolated from P6 cerebrum (top) and cerebellum 
(bottom) is shown for susceptible Krit1fl/fl and iECre;Krit1fl/fl littermates. N≥6 per group. 
No significant differences were detected. c, The number of B cells, NK cells, γδ T cells, 
CD4 T cells, CD8 T cells, eosinophils, neutrophils, and monocytes/macrophages isolated 
from P11 cerebrum (top) and cerebellum (bottom) is shown for susceptible Krit1fl/fl and 
iECre;Krit1fl/fl littermates. N≥6 per group. d–e, Frequency of RORγt+ CD4 T cells isolated 
from P6 and P11 cerebellum. N≥6 per group. Error bars of all graphs shown as s.e.m. and 
significance determined by unpaired, two-tailed Student’s t-test. *indicates p<0.05. Note that 
there is significant immune cell presence in the cerebellum of susceptible iECre;Krit1fl/fl 
animals at P11 but not at P6.
Extended Data Figure 3. Changes in the volume of CCM lesions are not accompanied by changes 
in total brain volume
The indicated total brain volumes were measured using microCT imaging. a–b, Brain 
volumes corresponding to the genetic rescue experiments shown in Fig. 2c–f, respectively. c, 
Brain volumes corresponding to the C-section/germ free fostering experiment shown in Fig. 
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4b–c. d, Brain volumes corresponding to the intergenerational antibiotic experiment shown 
in Fig. 6f–h and j. n.s. indicates p>0.05.
Extended Data Figure 4. Lineage tracing of the Cdh5(PAC)-CreERT2 (iECre) transgene in 
neonatal mice
a–c, R26-LSL-RFP, R26-CreERT2;R26-LSL-RFP, and Cdh5(PAC)-CreERT2;R26-LSL-RFP 
neonates were induced with doses of tamoxifen on P1+2 (two total doses) and CD45+;RFP+ 
hematopoietic cell numbers in the spleen and peripheral blood assessed at P10. N≥5 per 
group. Error bars shown as s.e.m. and significance determined by one-way ANOVA with 
Holm-Sidak correction for multiple comparisons. ***indicates p<0.001; n.s. indicates 
p>0.05. Note that the number of labeled hematopoietic cells in Cdh5(PAC)-CreERT2;R26-
LSL-RFP animals is indistinguishable from R26-LSL-RFP negative control animals, while 
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>90% of CD45+ cells were RFP+ in R26-CreERT2;R26-LSL-RFP positive control animals. 
d, Anti-RFP and anti-PECAM immunostaining of P10 hindbrains from Krit1fl/fl;R26-LSL-
RFP negative control and iECre;Krit1fl/fl;R26-LSL-RFP was performed to identify Cre+ 
descendants at the site of CCM formation. Note that all RFP+ cells in iECre;Krit1fl/fl;R26-
LSL-RFP animals are PECAM+, consistent with endothelial-specific Cre activity. Asterisk 
indicates CCM lesion. Results are representative of ≥ 3 per group. Scale bars, 100 μm.
Extended Data Figure 5. The Slco1c1(BAC)-CreERT2 (iBrECre) transgene expresses selectively in 
brain endothelial cells and iBrECre-driven deletion of Krit1 confers CCM formation in neonatal 
mice
a, R26-LSL-RFP, Cdh5(PAC)-CreERT2;R26-LSL-RFP and Slco1c1(BAC)-CreERT2;R26-
LSL-RFP neonates were induced with tamoxifen injection on P1+2 (two total doses). 
Immunostaining for RFP and PECAM was performed at P10 in the indicated tissues. Results 
are representative of at least three animals per group and three independent experiments. 
Scale bars, 100 μm. Note the presence of RFP+ PECAM+ cells in the brain, small intestine, 
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cecum, colon and liver of Cdh5(PAC)-CreERT2;R26-LSL-RFP animals, but only in the brain 
of Slco1c1(BAC)-CreERT2;R26-LSL-RFP animals. b, Visual (top) and corresponding 
microCT (bottom) images of brains from susceptible iBrECre;Krit1fl/+ and iBrECre;Krit1fl/fl 
P10 animals. Arrow indicates CCM lesions in the cerebrum. Scale bars, 1 mm. c, H&E 
staining of cerebellum (hindbrain) from the indicated animals (left). H&E staining of 
cerebrum (forebrain) from the indicated animals (middle). KLF4 and PECAM 
immunostaining from the indicated animals (right). Scale bars, 50 μm. Asterisks denote 
CCM lesions. N≥5 per group.
Extended Data Figure 6. CCM formation can be stimulated by IL-1β or poly(I:C) treatment
a, Schematic of the experimental design in which littermates receive a retro-orbital injection 
of the indicated cytokine or TLR ligand at P5 and P10 prior to tissue harvest and analysis at 
P17. b–m, Visual images and volumetric quantitation of CCM lesions in the hindbrains of 
P17 iECre;Ccm2fl/fl littermates injected with the indicated cytokines, TLR ligands, or 
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vehicle control are shown. Error bars shown as s.e.m. and significance determined by 
unpaired, two-tailed Student’s t-test. *indicates p<0.05; n.s. indicates p>0.05. Scale bars, 1 
mm.
Extended Data Figure 7. 16s rRNA sequencing results from susceptible and resistant Krit1fl/fl 
and Ccm2fl/fl dams
a, Heat map showing relative abundance of bacterial taxa (right) identified in susceptible 
(blue) and resistant (salmon) Krit1 (ccm1, purple) and Ccm2 (ccm2, green) animals (top). b, 
Box plots of bacterial taxa that demonstrated significant differential abundance in 
susceptible versus resistant animals and the relative abundance of those taxa. c, Boxplot of 
the Firmicutes [Ruminococcus] taxon that displayed significant differential abundance 
between Krit1 and Ccm2 genotypes. Note that the relative abundance of Bacteroidetes s24-7 
is anywhere from 10 to 10,000-fold greater than any other taxon. Significance (p<0.05) for b 
and c determined by linear mixed effects modeling with Benjamini-Hochberg correction for 
multiple comparisons.
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Extended Data Figure 8. Blockade of CCM formation by the TLR4 antagonist LPS-RS
a, Schematic of the experimental design in which iECre;Krit1fl/fl littermates receive retro-
orbital injections of the TLR4 antagonist LPS-RS. b, Visual (left) and microCT (right) 
images of hindbrains from vehicle or LPS-RS injected animals. c–d, Quantitation of CCM 
lesion and brain volume in iECre;Krit1fl/fl littermates treated with vehicle or LPS-RS. Error 
bars shown as s.e.m. and significance determined by unpaired, two-tailed Student’s t-test. 
**indicates p<0.01; n.s. indicates p>0.05. All scale bars, 1 mm.
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Extended Data Figure 9. CCM formation is stimulated by spontaneous abscess formation and 
not blocked by vancomycin
a, P10 hindbrains from Generation 3/Post ABX iECre;Krit1fl/fl littermates in the 
longitudinal antibiotic experiment described in Fig 6e–l. The animal with a large CCM 
lesion burden on the far right was found to have an abdominal abscess (circle, “absc”) and 
splenomegaly (arrow, lower right). Scale bar, 1 mm. b, Schematic of the experimental design 
in which cohoused, lesion susceptible iECre;Krit1fl/fl mating pairs were used to test the 
acute effect of vancomycin treatment on CCM formation. Offspring were studied after 
receiving maternal vehicle or vancomycin administered from E14.5 to P11. c–d, Visual 
images of hindbrains from representative offspring following vehicle or vancomycin 
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antibiotic treatment. Scale bars, 1 mm. e–f, Volumetric quantitation of CCM lesions and 
brain volumes in iECre;Krit1fl/fl littermates treated with vehicle or vancomycin. g–h, 
Relative quantitation of total neonatal gut bacterial load measured by qPCR of bacterial 
universal 16S or Firmicutes-specific rRNA gene copies. N≥6 per group. Error bars of all 
graphs shown as s.e.m. and significance determined by unpaired, two-tailed Student’s t-test. 
n.s. indicates p>0.05. ****indicates p<0.0001; n.s. indicates p>0.05.
Extended Data Figure 10. CCM formation is conferred to the offspring of resistant animals by 
fostering to Swiss-Webster mothers
a, Schematic of the experimental design in which timed matings of resistant iECre;Krit1fl/fl 
and resistant iECre;Ccm2fl/fl mating pairs were used to generate E19.5 offspring delivered 
by natural birth and raised by the birth mother or C-section/fostered to conventional Swiss-
Webster foster mothers. b–c, Visual images of hindbrains from P10 resistant iECre;Krit1fl/fl 
and iECre;Ccm2fl/fl offspring following natural delivery and nursing by resistant mothers or 
after C-section/fostering to Swiss-Webster mothers. N≥6 per group.
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Figure 1. CCM formation is stimulated by gram negative bacterial infection and intravenous 
LPS injection
a, Lesion formation in susceptible and resistant iECre;Ccm2fl/fl mice at P17. Dotted lines 
trace cerebellar white matter. Asterisks; CCM lesions Scale bars, 1 mm (left) and 100 μm 
(right). b, Hindbrains of resistant iECre;Ccm2fl/fl littermates without (top) and with (bottom) 
spontaneous abdominal gram negative abscess. Scale bars, 1 mm. Arrows; CCM lesions. c, 
The bacterial abscess (“absc”) identified in (b) contains gram negative bacteria (arrows). 
Scale bars, 4 mm (top) and 10μm (bottom). d, CCM formation in resistant iECre;Ccm2fl/fl 
littermates following injection with a live B. fragilis/autoclaved cecal contents mixture (B. 
fragilis) or ACC alone (ACC vehicle). Scale bars, 1 mm. e–f, Resistant iECre;Ccm2fl/fl 
responders exhibit splenic abscesses and increased spleen weight compared with non-
responders. g, CCM formation in resistant iECre;Ccm2fl/fl mice following vehicle or LPS 
treatment. Scale bars, 1 mm. h–i, Quantitation of lesion and total brain volumes. Error bars 
shown as s.e.m. and significance determined by one way ANOVA with Holm-Sidak 
correction for multiple comparisons or unpaired, two-tailed t-test. **** indicates p<0.0001; 
***indicates p<0.001; n.s. indicates p>0.05.
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Figure 2. CCM lesion formation requires endothelial TLR4/CD14 signaling
a, Injection of LPS at P5 drives CCM formation by P6 in susceptible iECre;Krit1fl/fl 
littermates. Scale bars, 1mm (white) and 50 μm (yellow). Arrows and arrowheads; CCM 
lesions. Dotted lines; cerebellar white matter. b, Gene expression in cerebellar endothelial 
cells isolated from the indicated littermates at P6. N≥3 per group. c–f, Genetic rescue of 
CCM formation with endothelial loss of TLR4 or global loss of CD14. Visual appearance of 
CCM lesions (above), corresponding microCT images (below), and lesion volume 
quantitation. Scale bars, 1mm. Error bars shown as s.e.m and significance determined by 
one-way ANOVA with Holm-Sidak correction for multiple comparisons. ****indicates 
p<0.0001; ***indicates p<0.001; **indicates p<0.01; n.s. indicates p>0.05.
Tang et al. Page 34
Nature. Author manuscript; available in PMC 2018 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Increased TLR4 or CD14 expression is associated with higher lesion number in familial 
CCM patients
a, SNPs in the 5′ genomic regions of TLR4 and CD14 associated with increased lesion 
numbers in familial CCM patients are shown relative to the transcriptional start site (TSS). 
b–c, Normalized microarray measurement of TLR4 and CD14 expression in whole blood 
cells from individuals in the general population with the indicated TLR4 rs10759930 and 
CD14 rs778587 genotypes. d, Representative MRI images of KRIT1 Q455X patients with 
raw lesion count and TLR4/CD14 SNP genotypes (RA; risk allele). e–f, Sex and age 
adjusted log(lesion burden) in KRIT1 Q455X patients with indicated genotypes. Error bars 
shown as 95% confidence intervals and significance determined by one-way ANOVA with 
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Holm-Sidak correction for multiple comparisons. ****indicates p<0.0001; ***indicates 
p<0.001; **indicates p<0.01; *indicates p<0.05.
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Figure 4. CCMs fail to form in most germ-free mice
a, Experimental design in which offspring of susceptible Krit1fl/fl females were fostered to 
conventional or germ-free Swiss-Webster mothers. b, Hindbrains from P10 offspring 
fostered in conventional (4/8 shown, top) or germ-free conditions (8/8 shown, bottom). c, 
Lesion volume quantitation of iECre;Krit1fl/fl hindbrains following C-section/fostering in 
conventional or germ-free conditions. d, Relative quantitation of neonatal gut bacterial load 
measured by qPCR of bacterial 16S rRNA gene copies. e, Relative quantitation of Krit1 
mRNA in lung endothelial cells (LEC) measured by qPCR. Red boxes indicate values for 
the single germ-free animal with significant lesions. Scale bars, 1 mm. Error bars shown as 
s.e.m. and significance determined by unpaired, two-tailed Student’s t-test. ****indicates 
p<0.0001; n.s. indicates p>0.05.
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Figure 5. CCM susceptibility is associated with increased levels of gram negative Bacteroidetes 
s24-7
a–c, Visual and microCT images of hindbrains from susceptible (top) and resistant (bottom) 
iECre;Krit1fl/fl and iECre;Ccm2fl/fl animals and susceptible iECre;Krit1fl/fl animals fostered 
to conventional Swiss-Webster (SW) mothers. Scale bars, 1 mm. d–e, Quantitation of lesion 
and brain volumes. Error bars shown as s.e.m. and significance determined by one-way 
ANOVA with Holm-Sidak correction for multiple comparisons. f–g, Principle Coordinates 
Analysis (PCoA) of unweighted and weighted UniFrac bacterial composition distances from 
the feces of susceptible and resistant Krit1fl/fl and Ccm2fl/fl mothers. P-values compare 
bacterial compositions in all resistant to all susceptible animals using PERMANOVA. h, 
Relative abundance boxplot of Bacteroidetes s24-7 in susceptible or resistant Krit1fl/fl or 
Ccm2fl/fl mothers and conventional SW foster mothers. Significance determined by linear 
mixed effects model with Benjamini-Hochberg correction for multiple comparisons. 
****indicates p<0.0001; ***indicates p<0.001; n.s. indicates p>0.05. Note: Conventional 
SW data from Figs. 4 and 5 are the same experiment.
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Figure 6. Preventing CCM formation by TLR4 antagonism and microbiome manipulation
a, Model of pathogenesis in which gram negative bacteria (GNB) in the gut are the source of 
LPS that enters circulating blood, activating luminal, brain endothelial TLR4 receptors. 
LPS-TLR4 stimulation drives MEKK3-KLF2/4 signaling to induce CCMs. b, Visual and 
microCT images of hindbrains from vehicle or Tak242 injected animals. c–d, Lesion and 
brain volume quantitation. e, Intergenerational experiment in which susceptible 
iECre;Krit1fl/fl mating pairs were used to test the acute and chronic effects of antibiotic 
treatment on CCM formation. f–h, Visual and corresponding microCT images of hindbrains 
from offspring of three generations from one mating pair, representative of three pairs. i, 
Relative quantitation of neonatal gut bacterial load measured by qPCR of the bacterial 16S 
rRNA gene. N=4 per group. j, Lesion volume quantitation. k–l, Relative quantitation of 
Bacteroidetes s24-7 (s24-7) load in the neonatal gut measured by qPCR of the s24-7 rRNA 
gene (two distinct primer sets). N≥8 per group. All scale bars, 1 mm. Error bars shown as 
s.e.m. or boxplot and significance determined by one-way ANOVA with Holm-Sidak 
correction for multiple comparisons. ****indicates p<0.0001; ***indicates p<0.001; 
**indicates p<0.01; *indicates p<0.05; n.s. indicates p>0.05.
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